Article
30 Mar 2026
Chicago U.S. Attorney’s Office Named Lead Prosecutorial Partner On Trade Fraud Task Force, Emphasizing DOJ’s Increased Use Of False Claims Act In Customs Fraud Cases
AUTHORS CONTENT
Article
26 Mar 2026
Alabama Court Dismisses Hospice Whistleblower Suit, Reinforcing Pleading Standards And First-to-File Protections Under The FCA
Article
25 Mar 2026
Future FCA Enforcement Expectations In Light Of Record-Breaking FY 2025 Recoveries And Administration Priorities
Article
08 Jul 2025
DOJ Civil Division Announces New Enforcement Priorities Under Trump Administration And FCA's Key Role
Article
27 Mar 2025
Fourth Circuit Allows Immediate Enforcement Of DEI Executive Orders: Implications For Federal Contractors And Grant Recipients
Article
18 Mar 2025
First Circuit Joins Circuit Split In Favor Of "But For" Causation Required To Show Falsity In AKS-Based False Claims Act Cases
Article
12 Feb 2025
DOJ Memoranda Take Aim At DEI-Related Private Sector Programs And Department Practices
Article
05 Nov 2024
U.S. Appeal In Zafirov May Lead To Circuit Split And SCOTUS Review Of Constitutionality Of FCA's Qui Tam Provisions
Article
15 Aug 2023
June 2023 FCA Settlement Wrap-Up: DOJ Continues To Crack Down On Health Care Fraud
Article
14 Aug 2023
DOJ Continues To Crack Down On Health Care Fraud Violations, Announcing Convictions And Enforcement Activity
Article
17 Jun 2022
False Claims Act Litigation Retrospective: How The Regulatory Sprint's Changes To The Stark Law Could Have Impacted The Halifax Litigation
Article
11 May 2022
DOJ Reaches $20 Million Agreement With Baycare Health Systems To Settle Claims Of Allegedly Improper Donations To Increase Medicaid Funding
Article
23 Sep 2021
Sutter Health's $90 Million FCA Settlement Highlights Enforcement Focus On Medicare Advantage Program Fraud
Article
03 Sep 2021
DOJ Revisits The "Brand Memorandum" And Restores The Use Of Agency Guidance Documents To Support False Claims Act Enforcement
Article
15 Jul 2021
FDA Publishes Guidance On The Enhanced System Under The DSCSA Going Into Effect On November 27, 2023
Article
05 Jul 2021
FDA Interprets Terms Used In Definitions Of Suspect And Illegitimate Product Under The DSCSA
Article
25 Jun 2021
FDA Publishes Guidance On The Identification And Notification Of Suspect Products As Part Of The Implementation Of The Drug Supply Chain Security Act
Article
23 Jun 2021
DOJ Announces $22 Million False Claims Act Settlement With The University Of Miami For Provider-Based Rule Violations Involving Laboratory Tests
Article
04 Jun 2021
DOJ Announces Establishment Of COVID-19 Fraud Enforcement Task Force
Article
31 May 2021
FDA Publishes Guidance On Remote Interactive Evaluations For Oversight Of Drug Manufacturing And Bioresearch Monitoring Facilities During The COVID-19 Public Health Emergency